Axitinib

Generic Name: Axitinib

Brand Names: Inlyta, Axitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈N_₄OS

CAS Number: 319460-85-0

Unique Ingredient Identifier: C9LVQ0YUXG

Background: Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...

Indication: Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Thyroid cancer

Associated Therapies: First Line Chemotherapy

Clinical Trials

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-12-24

Last Posted Date: 2022-09-16

Lead Sponsor: Pfizer

Target Recruit Count: 481

Registration Number: NCT04682587

Locations: 🇺🇸
Pfizer, New York, New York, United States

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Completed

Conditions: Kidney Neoplasms

Interventions: Drug: sunitinib
Drug: axitinib

First Posted Date: 2020-12-16

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 1205

Registration Number: NCT04669366

Locations: 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Axitinib

First Posted Date: 2020-11-19

Last Posted Date: 2021-02-01

Lead Sponsor: Ipsen

Target Recruit Count: 1540

Registration Number: NCT04637204

Locations: 🇬🇧
Ipsen Facility, Slough, United Kingdom

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sasanlimab Prefilled syringe
Drug: Sasanlimab
Drug: Encorafenib
Drug: Axitinib
Drug: SEA-TGT
Drug: Binimetinib

First Posted Date: 2020-10-14

Last Posted Date: 2024-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT04585815

Locations: 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States

and more 50 locations

NPC - AXEL Study : Axitinib-Avelumab

Phase 2

Active, not recruiting

Conditions: Recurrent or Metastatic NPC

Interventions: Drug: Axitinib
Drug: Avelumab

First Posted Date: 2020-09-24

Last Posted Date: 2024-10-30

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 43

Registration Number: NCT04562441

Locations: 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Drug: Axitinib

First Posted Date: 2020-09-07

Last Posted Date: 2024-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT04540705

Locations: 🇩🇪
Local Institution - 0044, Munich, Germany
🇺🇸
Local Institution - 0001, Saint Louis, Missouri, United States
🇩🇪
Local Institution - 0040, Jena, Germany

and more 34 locations

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Advanced Renal Cell Carcinoma

Interventions: Biological: MEDI5752
Drug: Axitinib
Drug: Lenvatinib

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-09

Lead Sponsor: MedImmune LLC

Target Recruit Count: 179

Registration Number: NCT04522323

Locations: 🇪🇸
Research Site, Valencia, Spain

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Advanced Melanoma
Unresectable Melanoma

Interventions: Drug: Nivolumab
Drug: Axitinib

First Posted Date: 2020-07-30

Last Posted Date: 2024-05-07

Lead Sponsor: Yana Najjar

Target Recruit Count: 31

Registration Number: NCT04493203

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Neoplasm Metastasis

Interventions: Drug: PF-07265807
Drug: Sasanlimab
Drug: Axitinib

First Posted Date: 2020-07-07

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 67

Registration Number: NCT04458259

Locations: 🇺🇸
Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸
Community Health Network Investigational Drug Services, Indianapolis, Indiana, United States
🇺🇸
Rocky Mountain Lions Eye Institute (RMLEI), Aurora, Colorado, United States

and more 52 locations

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Phase 2

Conditions: Advanced Cancer
Metastatic Kidney Cancer
Neoadjuvant Therapy

Interventions: Drug: Toripalimab
Drug: Axitinib

First Posted Date: 2020-05-13

Last Posted Date: 2020-05-13

Lead Sponsor: West China Hospital

Target Recruit Count: 40

Registration Number: NCT04385654

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy